A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2.
暂无分享,去创建一个
I. Nakamura | A. Saito | A. Matsui | K. Fujiwara | S. Mochida | S. Nagoshi | Masahiko Tanaka | K. Nishikawa | J. Funyu | Y. Koshima | Takeshi Yoshida | Chuichi Sekine | Youji Harada | N. Sotome | Kenichi Toshima | So Takegoshi | Masao Shiomi